Compare Stocks → Alert: Your Bank is Dying – Act Now or Lose Everything! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:SBTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSBTXSilverback Therapeutics$9.04+1.8%$9.11$2.80▼$8.97$325.96M0.6337,931 shs531,662 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSBTXSilverback Therapeutics+1.80%+0.67%-7.28%+4.51%+24.86%Alert: Your Bank is Dying – Act Now or Lose Everything! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationSBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSBTXSilverback TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthSBTXSilverback TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSBTXSilverback TherapeuticsN/A67.8767.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipSBTXSilverback Therapeutics34.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableSBTX, IMC, C4XD, and MTPH HeadlinesRecent News About These CompaniesMay 29, 2024 | americanbankingnews.comCritical Analysis: Biophytis (NASDAQ:BPTS) vs. Silverback Therapeutics (NASDAQ:SBTX)May 11, 2023 | uk.investing.comARS Pharmaceuticals Inc (SPRY)March 12, 2023 | wwf.org.ukWild IslesFebruary 24, 2023 | pharmaphorum.comA look back at RNA Therapeutics – day oneJanuary 24, 2023 | seekingalpha.comSPRY ARS Pharmaceuticals, Inc.November 22, 2022 | 247wallst.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 18, 2022 | nasdaq.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 8, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsOctober 28, 2022 | markets.businessinsider.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 24, 2022 | thepharmaletter.comFDA accepts ARS Pharma’s NDA for NeffyOctober 23, 2022 | kentuckytoday.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIOctober 21, 2022 | finance.yahoo.comSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisOctober 19, 2022 | aaii.comIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?October 12, 2022 | bakersfield.comSHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNSeptember 17, 2022 | markets.businessinsider.comINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTSeptember 15, 2022 | seekingalpha.comSBTX Silverback Therapeutics, Inc.September 6, 2022 | markets.businessinsider.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTAugust 23, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYAugust 17, 2022 | apnews.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXCompany DescriptionsSilverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.